標(biāo)題: Titlebook: Infectious Complications in Biologic and Targeted Therapies; Carlos Cervera,Jose Maria Aguado Book 2022 The Editor(s) (if applicable) and [打印本頁] 作者: Mosquito 時(shí)間: 2025-3-21 19:18
書目名稱Infectious Complications in Biologic and Targeted Therapies影響因子(影響力)
書目名稱Infectious Complications in Biologic and Targeted Therapies影響因子(影響力)學(xué)科排名
書目名稱Infectious Complications in Biologic and Targeted Therapies網(wǎng)絡(luò)公開度
書目名稱Infectious Complications in Biologic and Targeted Therapies網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Infectious Complications in Biologic and Targeted Therapies被引頻次
書目名稱Infectious Complications in Biologic and Targeted Therapies被引頻次學(xué)科排名
書目名稱Infectious Complications in Biologic and Targeted Therapies年度引用
書目名稱Infectious Complications in Biologic and Targeted Therapies年度引用學(xué)科排名
書目名稱Infectious Complications in Biologic and Targeted Therapies讀者反饋
書目名稱Infectious Complications in Biologic and Targeted Therapies讀者反饋學(xué)科排名
作者: rectum 時(shí)間: 2025-3-21 21:07
http://image.papertrans.cn/i/image/464503.jpg作者: 秘密會(huì)議 時(shí)間: 2025-3-22 00:38
https://doi.org/10.1007/978-3-031-11363-5Infection Prevention; Epidemiology; Disease Evaluation; Vaccination and Biologic Agents; Immune checkpoi作者: climax 時(shí)間: 2025-3-22 06:12
978-3-031-11365-9The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: 項(xiàng)目 時(shí)間: 2025-3-22 10:55
iche (portugal), June 17-21,2001. This Symposium was the direct continuation of the first two CMIS held in Lausanne (1992) and in Carry-Le-Rouet (1994). Other related meetings, in what concerns scientific topics and participants, took place in the nineties at La Grande Motte (1990), Vadstena (1996),作者: Aggressive 時(shí)間: 2025-3-22 16:13
Joel V. Chua,John W. Baddleye. from September 19th to 23rd. 1994, attended by 110 participants from 17 countries. This symposium was the continuation of the first CMIS held in 1992 in Lausanne. of the Symposium Euromech 273 "Unilateral Contact and Dry Friction" held in 1990 in La Grande Motte. France. and of the series of "Mee作者: ADAGE 時(shí)間: 2025-3-22 18:20
Malgorzata Mikulska,Diana Averbuchhe solution 50 years later for adhesive normal contact between a rigid sphere and a rigid plane. The resulting adhesive force was found to be . = 4., where . is the surface energy. The solution for the adhesive contact between elastic bodies was presented in 1971 by Johnson, Kendall, and Roberts (JK作者: 不再流行 時(shí)間: 2025-3-22 22:44
Juan Aguilar-Company,Isabel Ruiz-Campsfrom micro to mega and in different fields are shown: contac.This application-oriented book introduces readers to the associations and relationships between contact mechanics and friction, providing them with a deeper understanding of tribology. It addresses the related phenomena of contacts, adhesi作者: 信任 時(shí)間: 2025-3-23 02:22
Mosaab Alam,Allison Mah,Sara Belgariction pro- cesses, to reduce material losses due to wear, and to increase the service life of components. Contact Mechanics plays an important role in Tribology. Contact Mechanics studies the stress and strain states of bodies in contact; it is contact that leads to friction interaction and wear. 作者: GROWL 時(shí)間: 2025-3-23 08:32
Matteo Rinaldi,Giuseppe Ferraro,Maddalena Giannellaosses in friction pro- cesses, to reduce material losses due to wear, and to increase the service life of components. Contact Mechanics plays an important role in Tribology. Contact Mechanics studies the stress and strain states of bodies in contact; it is contact that leads to friction interaction 作者: thwart 時(shí)間: 2025-3-23 09:45 作者: Perigee 時(shí)間: 2025-3-23 14:16 作者: flaunt 時(shí)間: 2025-3-23 19:19 作者: 誤傳 時(shí)間: 2025-3-24 00:58
Eleftheria E. Kampouri,Jonathan Tschopp,Oriol Manuelmodeling of solids and structures in the context of finite deformations and frictional sliding. Based on some concepts of nonlinear continuum mechanics, the mortar approach is first presented for the more accessible case of mesh tying (also referred to as tied contact). Mortar methods for unilateral作者: glisten 時(shí)間: 2025-3-24 02:32 作者: Custodian 時(shí)間: 2025-3-24 08:10 作者: 協(xié)定 時(shí)間: 2025-3-24 13:17 作者: CLAM 時(shí)間: 2025-3-24 16:24 作者: 暫時(shí)別動(dòng) 時(shí)間: 2025-3-24 21:13 作者: exhibit 時(shí)間: 2025-3-24 23:32
Anti-tumor Necrosis Factor-Alpha Agentsmatoid arthritis to inflammatory bowel diseases. Development of TNF-α inhibitors (TNFI) has revolutionized the ability to treat these conditions, resulting in substantial improvement in clinical outcomes. Since the introduction of infliximab and etanercept in 1998, indications for the use of TNFI ha作者: 禁令 時(shí)間: 2025-3-25 06:14
CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4ver the past 20?years, many monoclonal antibodies targeting these antigens have been developed and introduced into clinical practice. Many of them are used successfully for the treatment of leukemia, lymphoma, multiple myeloma, and systemic autoimmune diseases (e.g. systemic ., Sjogren’s syndrome) b作者: 嚴(yán)厲批評(píng) 時(shí)間: 2025-3-25 08:54 作者: Customary 時(shí)間: 2025-3-25 14:30
Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agentsnd associated signaling pathways among cancer patients and to suggest recommendations..Anti-epidermal growth factor receptor monoclonal antibodies (cetuximab and panitumumab) are associated with an increased risk of neutropenia. They may also induce papulopustular rash which may predispose to second作者: 采納 時(shí)間: 2025-3-25 16:49
Interleukin-1 Targeted Agentsk of infectious complications associated with the use of interleukin-1 (IL-1) targeted therapy..: A narrative review was undertaken utilizing computer-based MEDLINE searches for each IL-1 targeting agent. Literature review was focused on available meta-analysis, randomized controlled trials (RCT), a作者: 巨頭 時(shí)間: 2025-3-25 22:54
Interleukin-6 Targeted Agentseceptor may result in severe and potentially life-threatening infections with significant discrepancy in both clinical and laboratory markers. Current evidence on the infection risk associated with the use of IL-6 or IL-6R-targeted agents consists mostly of studies including patients treated for a c作者: 抑制 時(shí)間: 2025-3-26 02:15 作者: aggravate 時(shí)間: 2025-3-26 07:31 作者: definition 時(shí)間: 2025-3-26 10:14
Immune Checkpoint Inhibitorsecificity and self-tolerance. The two major families of checkpoint inhibitors target the CTLA-4/B7s and the PD-1/PD-L1 axis. Inhibition of either of these two pathways intends to enhance the antitumor activity of lymphocytes. The risk of infections associated with checkpoint inhibition can be explai作者: Little 時(shí)間: 2025-3-26 15:16
α4-Integrin (and Other Leukocyte Integrin)-Targeting Agentsruitment of leukocytes from the vasculature to the tissues and are used as therapeutic targets to modulate inflammation. The monoclonal antibody natalizumab targets the α4 subunit of α4β1 and α4β7 integrins, implicated in the entry of lymphocytes in the central nervous system (CNS) and the gut mucos作者: Eulogy 時(shí)間: 2025-3-26 20:27 作者: Psychogenic 時(shí)間: 2025-3-26 21:17 作者: Hyaluronic-Acid 時(shí)間: 2025-3-27 04:59 作者: Obligatory 時(shí)間: 2025-3-27 06:14 作者: Exuberance 時(shí)間: 2025-3-27 12:52 作者: 津貼 時(shí)間: 2025-3-27 14:00 作者: N斯巴達(dá)人 時(shí)間: 2025-3-27 20:55
Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agentswed, no recommendation can be established on the benefit from antimicrobial prophylaxis, although an individualized infection risk assessment seems advisable, taking into account underlying diseases and previous or concomitant treatments.作者: flaggy 時(shí)間: 2025-3-27 22:35 作者: Spinal-Fusion 時(shí)間: 2025-3-28 03:49 作者: 誘惑 時(shí)間: 2025-3-28 08:30 作者: GILD 時(shí)間: 2025-3-28 14:12 作者: anus928 時(shí)間: 2025-3-28 17:30
α4-Integrin (and Other Leukocyte Integrin)-Targeting Agents lymphocytes in the CNS, leading to decreased immunosurveillance against JC virus (JCV). PML is not observed with vedolizumab, which has no effect on leukocyte trafficking to the CNS. The risk of PML development, a life-threatening disease, is associated with the patient’s JCV serostatus, the use of作者: 凝視 時(shí)間: 2025-3-28 22:03 作者: 詼諧 時(shí)間: 2025-3-29 00:44 作者: 寒冷 時(shí)間: 2025-3-29 06:27 作者: lavish 時(shí)間: 2025-3-29 11:09 作者: archenemy 時(shí)間: 2025-3-29 14:09
s that clinicians may face when evaluating these patients..This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies..978-3-031-11365-9978-3-031-11363-5作者: 種屬關(guān)系 時(shí)間: 2025-3-29 18:30 作者: Gingivitis 時(shí)間: 2025-3-29 20:21
Matteo Rinaldi,Giuseppe Ferraro,Maddalena Giannellaome of the problems included in the book were investigated together with my col- leagues Dr. M. N. Dobychin, Dr. O. G. Chekina, Dr. I. A. Soldatenkov, and Dr. E978-90-481-5102-8978-94-015-9048-8Series ISSN 0925-0042 Series E-ISSN 2214-7764 作者: painkillers 時(shí)間: 2025-3-30 00:14
Joel V. Chua,John W. Baddley the foundations are clear both from the mathematical and from the computational standpoints. Some of the difficulties met may be identified by saying that frictional contact is governed by resistance laws that are non smooth and whose flow rule is not associated with the yield criterion through the tradition978-1-4613-5817-6978-1-4615-1983-6作者: 概觀 時(shí)間: 2025-3-30 04:06 作者: DEFT 時(shí)間: 2025-3-30 10:41 作者: 使害羞 時(shí)間: 2025-3-30 13:14 作者: Canyon 時(shí)間: 2025-3-30 16:56 作者: 拋物線 時(shí)間: 2025-3-30 22:52
Eleftheria E. Kampouri,Jonathan Tschopp,Oriol Manueln procedures and new discretization techniques such as isogeometric analysis (IGA) using NURBS are discussed. Eventually, the great potential of mortar methods in the more general field of computational interface mechanics is exemplified through applications such as wear modeling and coupled thermo-作者: 悶熱 時(shí)間: 2025-3-31 02:57
Pedro Puerta-Alcalde,Nicole Garcia-Pouton,Carolina Garcia-Vidalch (Derjaguin, Kolloid Z 69:155–164, 1934) and (2) superposition of solutions to two non-adhesive contact problems (the Hertz-type and the Boussinesq-type problems). The JKR formalism may be used if the distance between the free surface of the material and the indenter surface increases rapidly at t作者: Increment 時(shí)間: 2025-3-31 07:34 作者: Neutropenia 時(shí)間: 2025-3-31 09:51
Infectious Complications in Biologic and Targeted Therapies978-3-031-11363-5作者: 建筑師 時(shí)間: 2025-3-31 16:12 作者: 飾帶 時(shí)間: 2025-3-31 18:10 作者: 共棲 時(shí)間: 2025-4-1 01:41 作者: 行業(yè) 時(shí)間: 2025-4-1 01:54
CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4low-up would be needed to determine the real risk of some rare infections. This chapter evaluates the incidence, risk factors, and proposed prevention for infectious complications related to these drugs.作者: CHARM 時(shí)間: 2025-4-1 06:42
